Literature DB >> 9517960

Activities of isoniazid alone and in combination with other drugs against Mycobacterium avium infection in beige mice.

L Fattorini1, Y Xiao, M Mattei, Y Li, E Iona, M L Ricci, O F Thoresen, R Creti, G Orefici.   

Abstract

Monotherapy with isoniazid or amikacin or clarithromycin or combinations of two of these drugs showed nil to modest therapeutic activity in beige mice infected with Mycobacterium avium. However, the combination of all three, isoniazid-amikacin-clarithromycin, markedly reduced CFUs in both spleens and lungs after 91 days of infection.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9517960      PMCID： PMC105526     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  13 in total

1.  Individualized therapy versus standard regimens in the treatment of Mycobacterium avium infections.

Authors:  L B Heifets; M D Iseman
Journal:  Am Rev Respir Dis       Date:  1991-07

Review 2.  Susceptibility testing of Mycobacterium avium complex isolates.

Authors:  L Heifets
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

3.  Activity of antimicrobial agents against Mycobacterium avium-intracellulare complex (MAC) strains isolated in Italy from AIDS-patients.

Authors:  L Fattorini; C Q Hu; S H Jin; C Santoro; A Y Tsang; M T Mascellino; F Mandler; G Orefici
Journal:  Zentralbl Bakteriol       Date:  1992-04

4.  Effectiveness of various antimicrobial agents against Mycobacterium avium complex in the beige mouse model.

Authors:  B Ji; N Lounis; C Truffot-Pernot; J Grosset
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

5.  Recommendations on prophylaxis and therapy for disseminated Mycobacterium avium complex disease in patients infected with the human immunodeficiency virus. Public Health Service Task Force on Prophylaxis and Therapy for Mycobacterium avium Complex.

Authors:  H Masur
Journal:  N Engl J Med       Date:  1993-09-16       Impact factor: 91.245

Review 6.  The Mycobacterium avium complex.

Authors:  C B Inderlied; C A Kemper; L E Bermudez
Journal:  Clin Microbiol Rev       Date:  1993-07       Impact factor: 26.132

7.  Therapy of multidrug-resistant tuberculosis: lessons from studies with mice.

Authors:  S P Klemens; M S DeStefano; M H Cynamon
Journal:  Antimicrob Agents Chemother       Date:  1993-11       Impact factor: 5.191

8.  In vitro and in vivo synergistic effect of isoniazid with streptomycin and clofazimine against Mycobacterium avium complex (MAC).

Authors:  M V Reddy; S Srinivasan; P R Gangadharam
Journal:  Tuber Lung Dis       Date:  1994-06

9.  In vitro and ex vivo activities of antimicrobial agents used in combination with clarithromycin, with or without amikacin, against Mycobacterium avium.

Authors:  L Fattorini; B Li; C Piersimoni; E Tortoli; Y Xiao; C Santoro; M L Ricci; G Orefici
Journal:  Antimicrob Agents Chemother       Date:  1995-03       Impact factor: 5.191

Review 10.  Tuberculosis in the AIDS era.

Authors:  K A Sepkowitz; J Raffalli; L Riley; T E Kiehn; D Armstrong
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132
View more
  2 in total

1.  Development of a firefly luciferase-based assay for determining antimicrobial susceptibility of Mycobacterium avium subsp. paratuberculosis.

Authors:  S L Williams; N B Harris; R G Barletta
Journal:  J Clin Microbiol       Date:  1999-02       Impact factor: 5.948

2.  Potent antimycobacterial activity of the pyridoxal isonicotinoyl hydrazone analog 2-pyridylcarboxaldehyde isonicotinoyl hydrazone: a lipophilic transport vehicle for isonicotinic acid hydrazide.

Authors:  Samantha Ellis; Danuta S Kalinowski; Lisa Leotta; Michael L H Huang; Peter Jelfs; Vitali Sintchenko; Des R Richardson; James A Triccas
Journal:  Mol Pharmacol       Date:  2013-11-15       Impact factor: 4.436
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.